Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation

Luis J. Cruz
* ,
Paul J. Tacken
,
Johan S. van der Schoot
ORCID logo ,
Felix Rueda
,
Ruurd Torensma
ORCID logo ,
Carl G. Figdor
*
Version 1 : Received: 9 April 2019 / Approved: 10 April 2019 / Online: 10 April 2019 (07:46:18 CEST)

A peer-reviewed article of this Preprint also exists.

Cruz, L.J.; Tacken, P.J.; van der Schoot, J.M.; Rueda, F.; Torensma, R.; Figdor, C.G. ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation. Molecules 2019, 24, 1825. Cruz, L.J.; Tacken, P.J.; van der Schoot, J.M.; Rueda, F.; Torensma, R.; Figdor, C.G. ICAM3-Fc Outperforms Receptor-Specific Antibodies Targeted Nanoparticles to Dendritic Cells for Cross-Presentation. Molecules 2019, 24, 1825.

Abstract

Abstract Optimal targeting of nanoparticles (NP) to dendritic cells (DCs) receptors to deliver cancer-specific antigens is key to an efficient induction of anti-tumor immune responses. Poly (lactic-co-glycolic acid) (PLGA) nanoparticles containing tètanus toxoid and gp100 melanoma-associated antigen, toll-like receptor adjuvants were targeted to the DC-SIGN receptor in DCs by specific humanized antibodies or by ICAM3-Fc fusion proteins mimicking natural ligand. Despite higher binding and uptake efficacy of anti-DC-SIGN antibody-targeted NP vaccines than ICAM3-Fc ligand, no difference were observed in DC activation markers CD80, CD83, CD86 and CCR7 induced. DCs loaded with NP coated with ICAM3-Fc appeared more potent in activating T cells via cross-presentation than antibody-coated NP vaccines. This fact could be very crucial in the design of new cancer vaccines.

Keywords

Receptor-specific antibodies; targeting; nanoparticles; dendritic cells; cross-presentation

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.